Anticoagulants Market - Forecasts from 2020 to 2025

The anticoagulants market was valued at US$26.293 billion in the year 2019 and is expected to show a good growth over the forecast period. The anticoagulant market is anticipated to propel at a decent CAGR throughout the forecast period due to a significant increase in the number of people with cardiovascular disease coupled with a growth in the number of cases with venous thromboembolism and arterial thrombosis. Anticoagulants are medicines that are used to prevent blood clots, especially for high-risk people. These medicines are taken by high-risk people who are more susceptible to clots in order to reduce the chances of them developing heart conditions of serious nature such as heart attacks and strokes. Blood clots are blood seals that can block the blood vessels of the body and further stop the blood from reaching the important organs of the body if they are formed at the wrong place, these organs include the brain, lungs or heart among others. The clots further can damage the organ to function properly as it also stops the flow of oxygen to that particular organ. Diseases such as atrial fibrillation can also lead to the formation of blood clots which can further lead to conditions such as heart failures, strokes and other complications related to heart. There is a significant increase in the prevalence of obesity around the globe which is also contributing the heart diseases related to blood clots. Furthermore, the risk of clotting in old people is also high due to weaker immune systems and other organs. Thus, the rising proportion of obese population along with a noteworthy increase in the global geriatric population are some of the key factors which are anticipated to drive the demand for these medicines in the coming years and propel the growth opportunities for the market to surge throughout the forecast period and beyond. Additionally, these medicines are also given to the patients during a heart-related surgery for the prevention of clot formations. Therefore, the growing number of heart surgeries worldwide is also expected to augment the market growth for anti-coagulants in the next five years. The use of these medicines helps the patient by preventing the clotting process which is increasing its adoption across the globe. These medicines are sometimes also referred to as blood thinners.

Rising prevalence of heart diseases

The growing number of people diagnosed with heart disease is the major driver of the anti-coagulants market. According to the World Health Organization (WHO), 17.9 million people die each year due to cardiovascular diseases (CVDs), an estimated 31% of all deaths worldwide. Increasing consumption of tobacco, unhealthy diet and physical inactivity are raising the risk of heart attacks and strokes. According to the Centre for Disease Control and Prevention, heart disease has been the major cause of death in the United States in which coronary heart disease is the most common type of heart disease. The rising obese population is one major cause of heart attack. According to the WHO, the worldwide prevalence of obesity nearly tripled between 1975 and 2016. All these factors are driving the demand anticipated to propel the demand for these medicines across the globe as doctors are focusing on a combination of risk factors for these diseases, implementing medical screening for individuals at risk, and then providing effective treatment to prevent disability and death while improving quality of life. Also, these medicines are suitable for the patients who suffered a heart attack as these medicines lower the risks of another heart attack. Furthermore, a growing number of heart attacks is propelling the demand for these medicines. For instance, as per the U.S. Department of Health and Human Services, every year 725,000 people have a heart attack out of which approximately 30% are those people who have already had a heart attack. Thereby, positively impacting the anti-coagulants market growth during the forecast period and beyond.

Deep Vein Thrombosis to hold a notable share

On the basis of application, the global anti-coagulants market has been segmented into atrial fibrillation, heart attacks, deep vein thrombosis, pulmonary embolism, and others. The deep vein thrombosis segment is anticipated to hold a significant share owing to its high incidence in developing countries. According to the U.S. Department of Health and Human Services, the prevalence of deep vein thrombosis accounts for 2 per 1000 people each year in the United States.

Furthermore, the anti-coagulants market for atrial fibrillation is anticipated to show a notable growth over the forecast period owing to the fact that this disease increases the risks of heart attacks, stroke and heart failure due to the formation of blood clots. Also, the growing prevalence of this disease across the globe is also a key factor that is expected to bolster the demand for anti-coagulants and thereby positively impacting the market growth in the coming years.

North America to hold a noteworthy share

Geographically, the global anti-coagulants market has been segmented into North America, South America, Europe, Middle East and Africa, and Asia Pacific. These regions have been further segmented into countries which hold a significant share in the market. North America is expected to hold a significantly large share in this market. The growth in this region is majorly attributed to state-of-the-art healthcare infrastructure which is expected to continue improving as industry players continue to funnel in huge investments in this sector in these regions. The market in the Asia Pacific is being driven by supportive initiatives by some governments in order to make expensive healthcare services accessible for people of all income groups.

Competitive Insights

Prominent key market players in the anti-coagulants market include Pfizer Inc., Bayer AG, Johnson & Johnson Services, Inc., Sanofi S.A., GlaxoSmithKline plc, and Portola Pharmaceuticals, Inc., among others. These companies hold a noteworthy share in the market on account of their good brand image and product offerings.

Major players in the anti-coagulants market have been covered along with their relative competitive position and strategies. The report also mentions recent deals and investments of different market players over the last two years.

Segmentation

By Drug Class
- Vitamin K antagonists (coumarin anticoagulants)
- Low molecular weight heparins (LMWH)
- Direct thrombin inhibitors
- Factor Xa Inhibitors

By Application
- Atrial Fibrillation
- Heart Attacks
- Deep Vein Thrombosis
- Pulmonary Embolism
- Others

By Geography
- North America
- USA
- Canada
- Mexico
- South America
- Brazil
- Argentina
- Others
- Europe
- Germany
- France
- United Kingdom
- Spain
- Others
- Middle East and Africa
- Saudi Arabia
- Israel
- Others
- Asia Pacific
- China
- Japan
- South Korea
- India
- Others